Compare NATH & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NATH | ZURA |
|---|---|---|
| Founded | 1916 | 2022 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.9M | 455.4M |
| IPO Year | 1996 | N/A |
| Metric | NATH | ZURA |
|---|---|---|
| Price | $98.58 | $5.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 18.5K | ★ 678.7K |
| Earning Date | 06-09-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.85 | N/A |
| Revenue | ★ $104,201,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.41 | ★ N/A |
| Revenue Growth | ★ 7.81 | N/A |
| 52 Week Low | $88.67 | $1.39 |
| 52 Week High | $113.59 | $7.25 |
| Indicator | NATH | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Nathan's Famous Inc is a branded licensor, wholesaler and retailer of products marketed under its brand. Its products are currently marketed for sale in thousands of locations, including supermarkets, mass merchandisers and club stores, selected foodservice locations and its company-owned and franchised restaurants throughout the United States and in twenty foreign countries. It considers itself to be in the foodservice industry. It has three segments Branded Product Program, Product Licensing, Restaurant Operations, of which majority of revenue is from Branded Product Program which derives from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors. It generates majority of revenue from United States.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.